LB54640
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Rhythm · Phase 2 · Completed · Enrollment 28
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Bivamelagon Low dose (200 milligrams [mg]) | n/r | n/r | n/r | n/r |
| Bivamelagon Middle dose (400 mg) | n/r | n/r | n/r | n/r |
| Bivamelagon High dose (600 mg) | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Open-label Bivamelagon | n/r | n/r | n/r | n/r |
Not shown
- Bivamelagon Low dose (200 milligrams [mg]): endpoint not reported
- Bivamelagon Middle dose (400 mg): endpoint not reported
- Bivamelagon High dose (600 mg): endpoint not reported
- Placebo: endpoint not reported
- Open-label Bivamelagon: endpoint not reported